Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Status:
RECRUITING
Trial end date:
2027-07-30
Target enrollment:
Participant gender:
Summary
The study is a Phase 2 clinical trial of the drug cirtuvivint as a second-line treatment for advanced soft tissue sarcomas. The study is being conducted in Spain and is expected to enroll approximately 25 patients in total. The primary objective of this Phase 2 study is to evaluate the efficacy of treatment with cirtuvivint.
Cirtuvivint is an anti-cancer medication developed by the U.S. company Biosplice Therapeutics, Inc. This drug is an inhibitor of the enzymes CLK1-4 and DYRK1-4 (molecules involved in the cell cycle) and is administered as oral tablets. This product is still under investigation and has not yet been approved in Europe.
Phase:
PHASE2
Details
Lead Sponsor:
Asociacin Europea y Latinoamericana SELNET para la Investigacin en Sarcomas